|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 36.22 USD | -0.52% |
|
-6.04% | -3.21% |
| Capitalization | 2.09B 1.8B 1.67B 1.56B 2.9B 189B 3.12B 19.26B 7.59B 90.29B 7.82B 7.66B 330B | P/E ratio 2025 * |
11.4x | P/E ratio 2026 * | 8.91x |
|---|---|---|---|---|---|
| Enterprise value | 1.51B 1.31B 1.22B 1.13B 2.11B 137B 2.27B 13.99B 5.51B 65.57B 5.68B 5.56B 239B | EV / Sales 2025 * |
1.75x | EV / Sales 2026 * | 1.22x |
| Free-Float |
67.64% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Harmony Biosciences Holdings, Inc.
| 1 day | -0.52% | ||
| 1 week | -6.04% | ||
| Current month | -3.21% | ||
| 1 month | -3.34% | ||
| 3 months | +39.85% | ||
| 6 months | +2.90% | ||
| Current year | -3.21% |
| 1 week | 34.68 |  | 38.65 |
| 1 month | 34.68 | | 39.6 |
| Current year | 34.68 | | 39.4 |
| 1 year | 25.52 | | 40.93 |
| 3 years | 18.61 | | 51.3 |
| 5 years | 18.61 | | 62.08 |
| 10 years | 18.61 | | 62.08 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jeffrey Dayno
CEO | Chief Executive Officer | 68 | 2023-01-05 |
| Director of Finance/CFO | 56 | 2021-03-28 | |
Kumar Budur
CTO | Chief Tech/Sci/R&D Officer | 55 | 2024-04-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Jeffrey Aronin
CHM | Chairman | 58 | 2017-07-24 |
Antonio Gracias
BRD | Director/Board Member | 55 | 2017-08-31 |
Juan Sabater
BRD | Director/Board Member | 61 | 2016-12-31 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +5.44% | 0.35% | 29 M€ | |
| +4.62% | 0.31% | 22 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.52% | -6.04% | -7.25% | -27.03% | 2.09B | |
| +0.53% | -2.37% | +43.09% | +194.99% | 930B | |
| -0.41% | +6.98% | +48.72% | +28.81% | 527B | |
| -1.11% | -2.60% | +24.94% | +43.67% | 379B | |
| 0.00% | +1.64% | +30.42% | +18.22% | 371B | |
| -0.14% | -0.55% | +30.09% | +22.96% | 292B | |
| +0.26% | +1.84% | +29.93% | +37.19% | 276B | |
| -1.93% | -1.54% | +11.14% | +0.04% | 270B | |
| -1.80% | +0.73% | -30.74% | -20.29% | 268B | |
| +0.12% | +1.32% | +21.43% | +24.97% | 178B | |
| Average | -0.48% | +0.03% | +20.18% | +32.35% | 349.3B | |
| Weighted average by Cap. | -0.30% | +0.50% | +29.22% | +67.48% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 864M 745M 693M 645M 1.2B 78.38B 1.29B 7.98B 3.14B 37.39B 3.24B 3.17B 137B | 1B 864M 804M 749M 1.39B 90.94B 1.5B 9.25B 3.65B 43.38B 3.76B 3.68B 158B |
| Net income | 193M 166M 155M 144M 268M 17.5B 289M 1.78B 702M 8.35B 723M 708M 30.48B | 250M 215M 200M 186M 347M 22.64B 374M 2.3B 908M 10.8B 936M 917M 39.44B |
| Net Debt | -571M -492M -458M -427M -795M -51.82B -855M -5.27B -2.08B -24.72B -2.14B -2.1B -90.26B | -860M -742M -690M -643M -1.2B -78.06B -1.29B -7.94B -3.13B -37.23B -3.23B -3.16B -136B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-01-16 | 36.22 $ | -0.52% | 648,690 |
| 26-01-15 | 36.41 $ | +1.03% | 774,906 |
| 26-01-14 | 36.04 $ | +0.78% | 924,507 |
| 26-01-13 | 35.76 $ | -6.56% | 1,245,349 |
| 26-01-12 | 38.27 $ | -0.73% | 694,069 |
Delayed Quote Nasdaq, January 16, 2026 at 04:00 pm EST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- HRMY Stock
Select your edition
All financial news and data tailored to specific country editions
